Loading organizations...
Huma.AI has raised $12.0M across 2 funding rounds.
Key people at Huma.AI.
Huma.AI has raised $12.0M in total across 2 funding rounds.
Huma.AI is a global healthcare AI company based in London, UK, that develops digital platforms to collect and integrate patient data from wearables, hospitals, and various medical devices for proactive care and research. Its Huma Cloud Platform enables the rapid development of FDA/EU-approved health applications, functioning as an app store for healthcare solutions that include symptom checkers and coaching. The company's platform-as-a-service model supports third-party developers, serving over 4,500 hospitals and clinics and reaching 50 million patients across 70 countries with its regulated health apps. In July 2024, Huma.AI secured over $80 million in Series D funding, achieving a near-$1 billion valuation, following the launch of its gen-AI-enabled platform and FDA Class I/II approval. The organization, led by founder and CEO Dan Vahdat, was established in 2011.
Key people at Huma.AI.
Huma.AI has raised $12.0M across 2 funding rounds. Most recently, it raised $10.0M Series A in February 2022.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Feb 1, 2022 | $10M Series A | — | A/O PropTech, Fusion Fund, Hatteras Venture Partners | Announced |
| Oct 1, 2019 | $2M Series U | — | A/O PropTech, Fusion Fund | Announced |
Huma.AI has raised $12.0M in total across 2 funding rounds.
Huma.AI's investors include A/O PropTech, Fusion Fund, Hatteras Venture Partners.
Huma.AI is a generative AI platform tailored for life sciences, automating insight generation from complex, unstructured data sources to accelerate decision-making in pharma and healthcare. It serves medical affairs teams, researchers, and life sciences professionals by replacing manual curation of siloed data—80% of which is unstructured—with a user-friendly, Google-like NLP interface that delivers verifiable answers in seconds[1][2][4][5]. The platform solves critical bottlenecks in drug development, real-world evidence (RWE) generation, literature reviews, and post-market surveillance, yielding 10x more results in minutes versus weeks for manual processes, as validated by global pharma companies[1][2].
Its growth momentum includes early collaboration with OpenAI in 2022, independent validation and deployment by multiple life sciences firms, and a single-tenant architecture ensuring secure, cited insights from internal/external data[2][4]. Led by CEO Susan Shiff, PhD, MBA (previously Lana Feng noted in some contexts), Huma.AI emphasizes an "expert-in-the-loop" ML approach, turning domain experts into data scientists for applications like HEOR, patient journey mapping, and HCP activity analysis[1][2][5].
Huma.AI emerged to tackle the inefficiencies of manual data curation in pharma, where siloed, unstructured datasets slow research and leave questions unanswered. The idea crystallized around generative AI's potential for life sciences, with the company launching collaboration with OpenAI in early 2022 to adapt large language models like those behind ChatGPT for domain-specific, accurate intelligence[2]. Founders and leadership, including CEO Susan Shiff, PhD, MBA, and CTO Eliot Levitt, drew from expertise in AI, pharma, and healthcare to build a platform prioritizing transparency and validation[5].
Early traction came from pharma validations, such as HEOR reviews showing dramatic efficiency gains and RWE applications mapping patient journeys faster than manual methods[1]. Pivotal moments include OpenAI's praise for its accuracy commitment and deployments proving superior results over alternatives, humanizing the team's focus on empowering overburdened medical affairs pros with intuitive tools[2][4].
Huma.AI rides the generative AI wave in life sciences, where exploding data volumes (80% unstructured) meet regulatory demands for verifiable RWE amid faster drug development cycles[1][2]. Timing aligns with LLM maturity post-ChatGPT, enabling secure, domain-specific tools that overcome AI's hallucination risks via citations and expert loops—critical as pharma invests in AI for HEOR, surveillance, and personalized care[2][4]. Market forces like digital transformation in med affairs and post-market needs favor it, influencing the ecosystem by accelerating scientific exchange, reducing manual toil, and setting standards for transparent AI in regulated sectors[2][5].
Huma.AI is poised to expand as a knowledge hub for life sciences, integrating evolving LLMs and broader data types to power AI-driven trials, virtual care, and global med affairs[2][4]. Trends like federated learning, multimodal AI, and regulatory AI approvals will shape its path, amplifying influence via partnerships and validations. As pharma leans on data for breakthroughs, Huma.AI's verifiable insights could redefine efficiency, evolving from insight automation to a cornerstone of AI-optimized healthcare—equipping pros to turn data floods into patient wins, much like its core mission promises[5].
